Although high-level MRD patients receiving preemptive IFN-α therapy showed outcomes similar to those receiving Chemo-DLI, it could not be concluded that IFN-α therapy was superior to Chemo-DLI in AML patients with MRD because this was not a randomized controlled trial (RCT). Here, IFNA2 is linked to acute myeloid leukemia.